Muvalaplin and Olpasiran Show Promise in Lowering Lp(a) Muvalaplin and Olpasiran Show Promise in Lowering Lp(a)

Oral muvalaplin lowered lipoprotein(a) in a phase 1 study, and injectable olpasiran did so in an extension of a phase 2 study, both with no adverse safety signals, researchers report.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Cardiology News Source Type: news